FDA slams Incyte's PD-1 over single-arm study, low response and trial deaths

The ever-growing PD-1 landscape could see a new entrant as an Incyte program is slated for an FDA decision next month. But first, the biotech will have to get through an adcomm Thursday, and briefing documents from the agency appear to cast doubt over how effective the candidate really is.